latest news releases from the newsroom
Sectra Extends Cooperation with R2 Technology
LINKOPING, Sweden, Aug. 24, 2005 (PRIMEZONE) -- Sectra, a major provider of enterprise and imaging center PACS, and R2 Technology, Inc., the leader in computer-aided detection (CAD), today announced an extended cooperation agreement. R2 will distribute the Sectra universal mammography workstation and other PACS components.
Trintech Group Plc
Trintech Reports Fiscal Year 2006 Second Quarter Financial Results
DUBLIN, Ireland and DALLAS, Aug. 24, 2005 (PRIMEZONE) -- Trintech Group Plc (Nasdaq:TTPA), a leading provider of transaction reconciliation and payment infrastructure solutions, today announced second quarter revenues of $12.6 million and a net loss for the quarter of $3.7 million, after a $3.9 million exceptional warranty charge relating to the extension of warranty periods for certain hardware products deployed in Europe. Excluding this once-off exceptional charge, Trintech generated net income for the second quarter of $225,000.
SmallCap Sentinel: Emergent Technologies Detailed in New Report as CompUSA and SoftNet 'Hook-Up'
IRVINE, Calif., Aug. 23, 2005 (PRIMEZONE) -- A report detailing the opportunities for emergent technologies in today's stock market has been made available at SmallCapSentinel.com. The report, "Technology Growth, Emerging Companies & Emerging Markets" is authored by analyst Francis Gaskins. Gaskins is a market analyst frequently seen on the nightly financial programs, and his report offers insight into past technology success stories while addressing present companies.
SmallCap Sentinel: Funds Flow to Stent Companies as Vioxx Lawsuit Changes Drug Landscape
IRVINE, Calif., Aug. 23, 2005 (PRIMEZONE) -- "The recent ruling against Merck (NYSE:MRK) further amplifies the biotechnology and pharmaceutical industry's insatiable appetite for new products," stated SmallCap Sentinel analyst, D.R. Clark. "Losing Vioxx as a profit superstar in their portfolio of offerings is an enormous loss as will be any potential punitive damages awarded to plaintiffs. This singular event paired with the pending horde of aging, drug-consuming Baby Boomers begins to explain why some emergent biotechnology and pharmaceutical technology companies are receiving healthy investment dollars of late. The demand is obvious."